Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05339386 · ClinicalTrials.gov registry record
Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension
A clinical trial of Pulmonary Arterial Hypertension, sponsored by University of Kansas Medical Center.
- Active
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT05339386 is a study of Pulmonary Arterial Hypertension that is active but no longer recruiting, run by University of Kansas Medical Center. The registered enrollment target is 10 participants, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05339386, a study of Pulmonary Arterial Hypertension, is active but no longer recruiting, sponsored by University of Kansas Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, hyperpolarized 129Xe MRI will be used to evaluate treatment efficacy in patients with pulmonary arterial hypertension (PAH). Participants will be imaged at 4 timepoints (baseline, 6 weeks post-therapy initiation, 12 weeks, and 18 weeks). Images will be analyzed to develop new biomarkers and to understand treatment effects.
Conditions Studied
Interventions
- DRUG Hyperpolarized Xe129
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-08-29 |
| Est. Completion | 2025-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05339386
The ClinicalTrials.gov registry entry for NCT05339386 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (98% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Hyperpolarized Xe129 is the first listed.
NCT05339386 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT05339386 about?
NCT05339386 is a clinical study titled "Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension". In this study, hyperpolarized 129Xe MRI will be used to evaluate treatment efficacy in patients with pulmonary arterial hypertension (PAH). Participants will be imaged at 4 timepoints (baseline, 6 weeks post-therapy initiation, 12 weeks, and 18 weeks). Images will be analyzed to develop new biomarke...
What is the current status of trial NCT05339386?
This trial is currently active not recruiting. The enrollment target is 10 participants. The study started on 2022-08-29. Estimated completion is 2025-03-31.
What conditions does trial NCT05339386 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT05339386?
The interventions under investigation include: Hyperpolarized Xe129 (DRUG).
Who is sponsoring clinical trial NCT05339386?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05339386 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
RECRUITING · NA
-
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
RECRUITING · Phase 3
-
A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension
RECRUITING · Phase 1
-
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
RECRUITING · Phase 2
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.